

FAX RECEIVED

MAY 24 2002

I hereby certify that this correspondence is being transmitted via facsimile to the U.S. Patent and Trademark Office in Washington, D.C. on May 23, 2002.

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D., Patent Attorney

COMMUNICATION GROUP 1600
Examining Group 1631
Patent Application
Docket No. GEN-T112XC1
Serial No. 09/326,402

OFFICIAL

#25
BP
5-28-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Mary K. Zeman
Art Unit : 1631
Applicants : Marta Blumenfeld, Lydie Bougueleret, Ilya Chumakov,
Serial No. : 09/326,402
Filed : June 4, 1999
Confirm. No. : 4132
For : Polymorphic Markers of Prostate Carcinoma Tumor Antigen-1
(PCTA-1)

U. S. Patent and Trademark Office
Washington, D.C.

COMMUNICATION

Attached hereto please find a copy of the Election filed by facsimile transmission on March 11, 2002, with copies of the facsimile transmission sheet, transaction report, and the RightFax Auto-Reply Facsimile Transmission report acknowledging receipt by the Patent Office on March 11, 2002. A telephone inquiry to the group receptionist indicates this Election has not been matched with the file at the Patent Office, and is enclosed herewith for consideration.

Respectfully submitted,

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800


Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
2421 NW 41st Street, Suite A-1
Gainesville, FL 32606-6669

FCE/jaj

Attachments: March 11, 2002 Election
Copies of March 11, 2002 Facsimile Cover Sheet and Transaction Report
Copy of March 11, 2002 RightFax Acknowledgement Report

#125

I hereby certify that this correspondence is being
facsimile transmitted to the United States Patent and
Trademark Office on March 11, 2002.


Frank C. Eisenschenk, Ph.D., Patent Attorney

ELECTION
Examining Group 1631
Patent Application
Docket No. GEN-T112XC1
Serial No. 09/326,402

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Mary K. Zeman
Art Unit : 1631
Applicants : Marta Blumenfeld, Lydie Bougueleret, Iyla Chumakov
Serial No. : 09/326,402
Filed : June 4, 1999
Conf. No. : 4132
For : Polymorphic Markers of Prostate Carcinoma Tumor Antigen-1
(PCTA-1)

Assistant Commissioner for Patents
Washington, D.C. 20231

ELECTION

Sir:

In response to the restriction requirement of February 11, 2002, Applicants elect, with
traverse, the single polymorphic site at position 402 of SEQ ID NO:12.

Remarks

Claims 121-141, 150-152, and 163-182 are pending and subject to a restriction requirement
in this application. Therefore, claims 121-141, 150-152, and 163-182 are drawn to the elected
invention.

Applicants respectfully traverse the restriction requirement as set forth in the Office Action of
April 18, 2001 and request that the Examiner rejoin the inventions. It is respectfully submitted that
rejoinder of the inventions would not create an undue search or examination burden on the Examiner
or the Patent Office.

FACSIMILE COVER SHEET

SALIWANCHIK, LLOYD & SALIWANCHIK

A Professional Association
2421 N.W. 41st Street
Suite A-1
Gainesville, FL 32606

Telephone (352) 375-8100
Facsimile (352) 372-5800

TO: Examiner Mary K. Zeman

FROM: Frank C. Eisenschenk, Ph.D.
(Reg. No. 45,332)

COMPANY: U.S. Patent & Trademark Office,
Art Unit 1631

DATE: March 11, 2002

FAX NO.: (703) 872-9306

NO. OF PAGES:
(INCLUDING COVER SHEET) 4

SUBJECT/MESSAGE:

Re: U.S. Patent Application Docket No. GEN-T112XC1

**POLYMORPHIC MARKERS OF PROSTATE CARCINOMA TUMOR
ANTIGEN-1 (PCTA-1)**

(Blumenfeld *et al.*)

Serial No. 09/326,402; Filed June 4, 1999

**THIS IS AN OFFICIAL DOCUMENT.
PLEASE DELIVER IMMEDIATELY. Thank you.**

Attachment: Election

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.